Lynx Bioscience LLC

Next Generation Omics Technologies

Lynx bio has expertise to discovery and validation of innovative disease modifying targets across different therapeutic areas as well as aid target deconvolution following a phenotypic screen.

Supporting Drug Mechanism of Action Studies (MoA)

Drugs fails in clinical trials for two reasons. Either the Intended target is wrong or toxicity from non-specific drug binding targets.

Drug Discovery

Proteomics solutions for drug discovery

Lynx Bioscience Omics approaches enables informed decisions at different stages of the drug discovery process. Our Expertise and technologies support both traditional, target-based drug discovery and phenotypic, chemical genetics-based drug discovery.